• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on therapeutic targets >MicroRNA-21: A therapeutic target for reversing drug resistance in cancer
【24h】

MicroRNA-21: A therapeutic target for reversing drug resistance in cancer

机译：MicroRNA-21：逆转癌症耐药性的治疗靶标

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Drug resistance is a major clinical obstacle to the successful treatment of human cancer. The microRNAs-21 (miR-21), an oncomiR, may play an important role in the progress of drug resistance. Areas covered: This review covers all related literature on miR-21 in drug resistance of human cancers and analyzes the expression, biological functions and targets of it. This study also envisages future developments toward its clinical and therapeutic applications in cancer treatment. Expert opinion: The miR-21 may promote the drug resistance of various cancers. Inhibitors of miR-21 may function as effective approaches for reversing drug resistance in cancer cells. There is a tough way from discovering the function of miR-21 to clinical use. Further understanding of miR-21-mediated signaling pathways will help to promote the therapeutic-clinical use of miR-21 in cancer.
机译：简介：耐药性是成功治疗人类癌症的主要临床障碍。微小RNA-21（miR-21）是一种癌基因，可能在耐药性发展中起重要作用。涵盖的领域：这篇综述涵盖了有关miR-21在人类癌症耐药中的所有相关文献，并分析了其表达，生物学功能和靶标。该研究还设想了其在癌症治疗中的临床和治疗应用的未来发展。专家意见：miR-21可能会促进各种癌症的耐药性。 miR-21抑制剂可能是逆转癌细胞耐药性的有效方法。从发现miR-21的功能到临床使用，这是一个艰难的途径。对miR-21介导的信号通路的进一步了解将有助于促进miR-21在癌症中的治疗性临床应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号